Papers: 22 Nov 2013 - 29 Nov 2013
Meaningful improvement in walking performance after Botulinum Neurotoxin A (BoNT-A) in chronic spastic patients.
Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.
Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI?
Erythrocytes' antioxidative capacity as a potential marker of oxidative stress intensity in neuroinflammation.
The reliability and validity study of the Kinesthetic and Visual Imagery Questionnaire in individuals with Multiple Sclerosis.
Retinal Layer Segmentation in Patients with Multiple Sclerosis Using Spectral Domain Optical Coherence Tomography.
Down-regulation of Myelin Gene Expression in Human Oligodendrocytes by Nitric Oxide: Implications for Demyelination in Multiple Sclerosis.
Profile of Circulatory Metabolites in a Relapsing-remitting Animal Model of Multiple Sclerosis using Global Metabolomics.
A multicentre prospective study of Guillain-Barre Syndrome in Japan: a focus on the incidence of subtypes.
Contrast enhanced MR venography with gadofosveset trisodium: Evaluation of the intracranial and extracranial venous system.
Electrophysiological features of POEMS syndrome and chronic inflammatory demyelinating polyneuropathy.
PERK Activation Preserves the Viability and Function of Remyelinating Oligodendrocytes in Immune-Mediated Demyelinating Diseases.
CD4(+)NKG2D(+) T Cells Exhibit Enhanced Migratory and Encephalitogenic Properties in Neuroinflammation.
Visual search as a tool for a quick and reliable assessment of cognitive functions in patients with multiple sclerosis.
Clinical Manifestations and Spinal Cord Magnetic Resonance Imaging Findings in Chinese Neuromyelitis Optica Patients.
Disclosure of diagnosis of multiple sclerosis in the workplace positively affects employment status and job tenure.
Tellurium Compound AS101 Ameliorates Experimental Autoimmune Encephalomyelitis by VLA-4 Inhibition and Suppression of Monocyte and T Cell Infiltration into the CNS.
Intravenous immunoglobulin preparation attenuates neurological signs in rat experimental autoimmune neuritis with the suppression of macrophage inflammatory protein -1α expression.
Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS).
A case of neuromyelitis optica harboring both anti-aquaporin-4 antibodies and a pathogenic mitochondrial DNA mutation for Leber's hereditary optic neuropathy.
Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects.
Feasibility of the Use of Combinatorial Chemokine Arrays to Study Blood and CSF in Multiple Sclerosis.
Correction: Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis.
Distribution of CD4(pos) -, CD8(pos) - and Regulatory T Cells in the Upper and Lower Gastrointestinal Tract in Healthy Young Subjects.
Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis.
Accurate white matter lesion segmentation by k nearest neighbor classification with tissue type priors (kNN-TTPs).
C-ANCA positive necrotising scleritis and multiple sclerosis compatible with ocular Wegener: treatment with rituximab.
Review of Clinical Applications of Scalp Acupuncture for Paralysis: An Excerpt From Chinese Scalp Acupuncture.
A Patient-defined "Best Case" of Multiple Sclerosis Related to the Use of Complementary and Alternative Medicine.
A prospective study of "undiagnosed" isolated myelopathy: II. Value of magnetic resonance imaging, evoked potentials and CSF analysis.
Central defects of autonomic function in secondary progressive multiple sclerosis: observations based on cardiovascular and growth hormone responses to clonidine.
The role of tumour necrosis factor α in the pathogenesis of multiple sclerosis, and pentoxifylline as a possible pharmacotherapeutic intervention.
Natural interferon-beta in chronic progressive multiple sclerosis: results after 2 years of treatment and 2 years of follow up.
Everyday memory impairment, neuroradiological findings and physical disability in multiple sclerosis.